Royal Bank Of Canada Reaffirms "Outperform" Rating for Definium Therapeutics (NASDAQ:DFTX)

Key Points

• Royal Bank of Canada reaffirmed its “Outperform” rating on Definium Therapeutics and set a $66 price target, implying approximately 71% upside from the stock’s reported $38.60 price.
• Analyst sentiment is broadly positive: Definium has an average “Buy” rating and a consensus price target of $63, though one analyst downgraded the stock to “Sell.”
• The company reported quarterly EPS of negative $1.44, missing the consensus estimate of negative $0.55; analysts expect a full-year loss of approximately $3.02 per share.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Royal Bank Of Canada in a report released on Friday, Benzinga reports. They presently have a $66.00 price target on the stock. Royal Bank Of Canada's target price would suggest a potential upside of 70.98% from the stock's current price.

A number of other equities analysts have also commented on DFTX. Oppenheimer restated an "outperform" rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen lowered shares of Definium Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Stifel Nicolaus increased their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Robert W. Baird upped their price target on shares of Definium Therapeutics from $57.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, August 13th. Finally, Wells Fargo & Company raised their price target on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Definium Therapeutics currently has an average rating of "Buy" and a consensus target price of $63.00.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $38.60 on Friday. The business's fifty day moving average is $43.11 and its 200 day moving average is $30.17. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of -11.25 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a 52-week low of $8.77 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts predict that Definium Therapeutics will post -3.02 EPS for the current year.

Insider Transactions at Definium Therapeutics

In related news, insider Matthew T. Wiley sold 2,867 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares in the company, valued at $7,863,723.99. The trade was a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider directly owned 320,571 shares of the company's stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 67,119 shares of company stock valued at $2,887,496 over the last 90 days. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System purchased a new stake in shares of Definium Therapeutics in the 2nd quarter valued at $283,999,000. Avoro Capital Advisors LLC purchased a new position in Definium Therapeutics in the 4th quarter worth $66,950,000. Commodore Capital LP lifted its stake in Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock worth $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Wellington Management Group LLP bought a new stake in Definium Therapeutics in the second quarter worth $138,755,000. Finally, Janus Henderson Group PLC boosted its position in Definium Therapeutics by 8,513.2% during the fourth quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company's stock valued at $32,256,000 after buying an additional 2,383,696 shares during the period. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.